Search clinical trials for: ALXN2050

Total 56 results

Alexion Pharmaceuticals

Completed

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Healthy

United States
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Alexion Pharmaceuticals, Inc.

Active, not recruiting

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis | Myasthenia Gravis

United States, Spain, Korea, Republic of, Canada, Germany, Italy, Serbia, Taiwan
Alexion

Completed

Study of ALXN2050 in Participants With Renal Impairment

Healthy | Renal Impairment

United States
Alexion

Recruiting

Study of ALXN2050 in Participants With Hepatic Impairment

Healthy | Impaired Hepatic Function

United States
Alexion Pharmaceuticals

Completed

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

Healthy

United States
Alexion

Active, not recruiting

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Italy, Canada, Korea, Republic of, New Zealand, Spain, Turkey
Alexion Pharmaceuticals, Inc.

Recruiting

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

Healthy

United Kingdom
Alexion Pharmaceuticals, Inc.
Eidos Therapeutics, a BridgeBio company

Active, not recruiting

A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM

Symptomatic Transthyretin Amyloid Cardiomyopathy

Japan
Alexion Pharmaceuticals
Celerion

Completed

Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Lupus Nephritis | Immunoglobulin A Nephropathy | IgAN | LN

Australia, Spain, United Kingdom, China, Germany, Italy, Argentina, Peru, Korea, Republic of, Taiwan, Thailand, United States, Serbia, Israel, Brazil, Turkey, Mexico, Russian Federation
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Single-dose ALXN2050 in Healthy Adults

Healthy

New Zealand
Eidos Therapeutics, a BridgeBio company

Completed

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM)

Heart Diseases | Amyloidosis | Cardiomyopathies | Transthyretin Amyloidosis | Amyloid Cardiomyopathy

United States, Netherlands, Ireland, Canada, Italy, Spain, Belgium, New Zealand, Israel, Australia, Portugal, Brazil, Poland, Czechia, Denmark, Greece, Korea, Republic of, United Kingdom
Alexion
Celerion

Completed

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

Healthy

United Kingdom
Alexion Pharmaceuticals

Completed

A Study of the Effects of Food and Age on Danicopan

Healthy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Multiple Doses of ALXN2050 in Healthy Adults

Healthy

New Zealand
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic Atrophy

United States, France, Germany, Italy, Spain, Korea, Republic of, United Kingdom, Canada, Japan, Czechia, Australia, Latvia, Hungary, Slovakia
Alexion Pharmaceuticals, Inc.

Available

Danicopan Early Access Program

Paroxysmal Nocturnal Hemoglobinuria | PNH | Extravascular Hemolysis
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (MULBERRY)

Hypophosphatasia

United States, Taiwan, Thailand, Vietnam, United Kingdom, Korea, Republic of, Israel, Italy, Australia, Turkey, France, Poland, Germany, Spain, Belgium, China, Canada, Brazil, Argentina, Mexico
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (HICKORY)

Hypophosphatasia

Italy, Spain, Korea, Republic of, Belgium, Germany, United States, China, France, Taiwan, Austria, Japan, India, Australia, Argentina, Israel, Poland, Turkey, Brazil, Thailand, United Kingdom, Canada, Slovakia, Czechia
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Radiolabeled Danicopan in Healthy Male Participants

Healthy

New Zealand
Alexion Pharmaceuticals

Completed

Study of Danicopan in Participants of Japanese Descent

Healthy

Australia
Alexion

Terminated

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

IC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative Glomerulonephritis

United States, Australia, Belgium, Italy, Netherlands
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of a Single Dose of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction

Healthy | Renal Dysfunction

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, New Zealand, Korea, Republic of, Italy
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

United States, Japan, Italy, Germany, Turkey, India, Australia, United Kingdom, Argentina, France, Canada
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Multiple Doses of Danicopan in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Danicopan in Participants With Hepatic Impairment

Hepatic Impairment

United States
Alexion Pharmaceuticals
Population Health Research Institute; Portola Pharmaceuticals, LLC (a wholly...

Completed

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

Bleeding

United States, Belgium, Canada, France, Germany, Japan, Netherlands, Spain, United Kingdom
Alexion Pharmaceuticals

Terminated

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Multiple Myeloma | B-cell Chronic Lymphocytic Leukemia

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and III

Netherlands, Australia, Belgium
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants

Healthy

New Zealand
Alexion Pharmaceuticals, Inc.

Recruiting

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (DepleTTR-CM)

Transthyretin Amyloid Cardiomyopathy

United States, Spain, United Kingdom, Norway, Israel, Korea, Republic of, Belgium, France, Germany, Italy, Japan, China, Australia, Argentina, Austria, Taiwan, Switzerland, Canada, Sweden, Poland, Denmark, Turkey, Brazil, Netherlands, G... and more
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1850 in Participants With Hypophosphatasia (HPP)

Hypophosphatasia

United States
Alexion Pharmaceuticals
Quintiles, Inc.

Terminated

Study of Samalizumab in Patients With Advanced Cancer

Advanced Solid Tumors

United States
Alexion Pharmaceuticals
Celerion

Completed

Study of the Metabolism of Danicopan in Healthy Adults

Healthy

United States
Alexion Pharmaceuticals
Celerion

Completed

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Healthy

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants

Healthy

United Kingdom
Alexion

Completed

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Healthy Participants

United States
Alexion

Completed

Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants

Healthy

United States
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
Alexion Pharmaceuticals, Inc.

Completed

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

Healthy

United Kingdom
Virginia Commonwealth University
American Heart Association

Completed

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

Cardiovascular Risk | Insulin Sensitivity | Perimenopausal Disorder

United States
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Completed

A Study of the Cardiac Effects of Danicopan in Healthy Adults

Healthy

United States
Alexion Pharmaceuticals
Celerion; Achillion, a wholly owned subsidiary of Alexion

Completed

A Drug Interaction Study of ACH-0145228

Healthy

United States

Search clinical trials for: ALXN2050

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations